FI963779L - MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa - Google Patents

MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa Download PDF

Info

Publication number
FI963779L
FI963779L FI963779A FI963779A FI963779L FI 963779 L FI963779 L FI 963779L FI 963779 A FI963779 A FI 963779A FI 963779 A FI963779 A FI 963779A FI 963779 L FI963779 L FI 963779L
Authority
FI
Finland
Prior art keywords
hla
molecules
complex
peptides derived
isolated peptides
Prior art date
Application number
FI963779A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963779A0 (fi
FI963779A7 (fi
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Der Bruggen Pierre Van
Pierre Coulie
Thomas Gajewski
Cornelis J M Melief
M W Visseren
W M Kast
Original Assignee
Ludwig Inst Cancer Res
Cancellor Masters And Scholars
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Inst Cancer Res, Cancellor Masters And Scholars, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of FI963779L publication Critical patent/FI963779L/fi
Publication of FI963779A0 publication Critical patent/FI963779A0/fi
Publication of FI963779A7 publication Critical patent/FI963779A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
FI963779A 1994-03-24 1995-03-22 MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptid ejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa FI963779A7 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003657 WO1995025740A1 (en) 1994-03-24 1995-03-22 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Publications (3)

Publication Number Publication Date
FI963779L true FI963779L (fi) 1996-09-23
FI963779A0 FI963779A0 (fi) 1996-09-23
FI963779A7 FI963779A7 (fi) 1996-09-23

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963779A FI963779A7 (fi) 1994-03-24 1995-03-22 MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptid ejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa

Country Status (16)

Country Link
US (1) US5851523A (de)
EP (2) EP0960622A3 (de)
JP (1) JP3536179B2 (de)
CN (1) CN1151170C (de)
AT (1) ATE198336T1 (de)
AU (1) AU698781B2 (de)
CA (1) CA2186004C (de)
DE (1) DE69519748T2 (de)
DK (1) DK0804483T3 (de)
ES (1) ES2154728T3 (de)
FI (1) FI963779A7 (de)
GR (1) GR3035636T3 (de)
NO (1) NO963919L (de)
NZ (1) NZ283587A (de)
PT (1) PT804483E (de)
WO (1) WO1995025740A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
DE69610483T2 (de) * 1996-01-18 2001-06-13 Aventis Pharma Deutschland Gmbh In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen
NZ501752A (en) * 1997-06-23 2000-12-22 Ludwig Inst Cancer Res Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP3184637A1 (de) * 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Komplexe aus säugetier-interleukin-12 p40 und interleukin b30, antikörper, verwendung in pharmazeutischen zusammensetzungen
DE60038304T3 (de) * 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
KR20020047249A (ko) * 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
KR20100061477A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ａｓｎ-ａｓｐ-ａｓｐ-ｃｙｓ-ｇｌｕ-ｌｅｕ-ｃｙｓ-ｖａｌ-ａｓｎ-ｖａｌ-ａｌａ-ｃｙｓ-ｔｈｒ-ｇｌｙ-ｃｙｓ-ｌｅｕ-ｏｈ 단독 또는 펩티드 ｔｈｒ-ｔｈｒ-ｓｅｒ-ｇｌｎ-ｖａｌ-ａｒｇ-ｐｒｏ-ａｒｇ-ｏｈ와의 배합물의 용도
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用

Also Published As

Publication number Publication date
NO963919L (no) 1996-11-20
ES2154728T3 (es) 2001-04-16
CN1150805A (zh) 1997-05-28
EP0804483A1 (de) 1997-11-05
WO1995025740A1 (en) 1995-09-28
GR3035636T3 (en) 2001-06-29
AU2192895A (en) 1995-10-09
CA2186004C (en) 2008-09-23
EP0804483A4 (de) 1998-05-20
EP0804483B1 (de) 2000-12-27
EP0960622A3 (de) 1999-12-22
EP0960622A2 (de) 1999-12-01
PT804483E (pt) 2001-06-29
DE69519748D1 (de) 2001-02-01
US5851523A (en) 1998-12-22
JPH10504518A (ja) 1998-05-06
FI963779A0 (fi) 1996-09-23
NO963919D0 (no) 1996-09-19
DK0804483T3 (da) 2001-02-12
NZ283587A (en) 1998-04-27
CA2186004A1 (en) 1995-09-28
AU698781B2 (en) 1998-11-05
FI963779A7 (fi) 1996-09-23
ATE198336T1 (de) 2001-01-15
JP3536179B2 (ja) 2004-06-07
DE69519748T2 (de) 2001-10-18
CN1151170C (zh) 2004-05-26

Similar Documents

Publication Publication Date Title
FI963779A7 (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptid ejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
ZA952374B (en) Isolated peptides derived from MAGE antigen precursors which complex with HLA-A2 molecules and uses thereof
FI963780L (fi) Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä peptidejä ja niiden käyttöjä
NO902744L (no) Forbedret haarkondisjoneringshampo.
PT1093381E (pt) Peptidos antigenicos derivados de telomerase
FI963033L (fi) Tuumorirejektioantigeenin esiasteeseen MAGE-1 sitoutuvia monoklonaalisia vasta-aineita, rekombinantti-MAGE-1 ja MAGE-1-peräisiä immunogeenisia peptidejä
EP0594436A3 (de) Gewebefesthaltende Feder.
DE69433406T2 (de) Antikörper gegen cd40
FI963781L (fi) Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä
FI905003L (fi) Glykosaminoglykan modifierat protein.
DK0972024T3 (da) Tumorsuppressor designeret TS10Q23.3
DE69534325D1 (de) Peptide zur behandlung von krebs
TR199500915A2 (tr) Peptidler.
CA2246222A1 (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
FI912344A0 (fi) Kompressionsskarv foer glasoegon.
DE59106163D1 (de) Mittel zur festigung der haare.
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
NO904898L (no) Baaren filtreringsmembran og fremgangsmaate for fremstilling av denne.
FI921582L (fi) Fibronektin-bindningsprotein.
ITGE950051V0 (it) Centina di sostegno di copertura di contenitori superiormente aperti.
NO901129L (no) Fremgangsmaate ved fremstilling av sdk-peptider.
GB9721432D0 (en) Improved production of antibodies through the use of antigen antibody complexes
ES1034081Y (es) Portamechas para expositores de peluqueria.
NZ320837A (en) Peptides derived from tumor rejection antigen precursors and presented by hla-b44 useful in diagnostic and therapeutic methodologies